Welcome to our dedicated page for Bausch + Lomb Corporation SEC filings (Ticker: BLCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bausch + Lomb Corporation (BLCO) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, drawn directly from the EDGAR system. As a Canadian-incorporated issuer with common shares listed on the New York Stock Exchange and the Toronto Stock Exchange, Bausch + Lomb files annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, along with exhibits such as credit agreements, indentures and press releases.
For an eye health company operating in vision care, surgical products and ophthalmic pharmaceuticals, these filings contain detailed information on segment performance, risk factors, capital structure and governance. Recent Form 8-K filings describe material events including secured notes offerings, amendments to the company’s credit and guaranty agreement, creation of new term loan tranches and revolving credit facilities, refinancing of existing borrowings, quarterly financial results, investor day materials and changes in the composition of the board of directors.
Investors can use this page to review Bausch + Lomb’s disclosures on direct financial obligations, covenants, leverage ratios and maturity profiles, as well as governance items such as director appointments, committee assignments and executive compensation arrangements referenced in current reports. Over time, the archive will also include annual 10-K reports and quarterly 10-Q reports, which provide more comprehensive discussions of the company’s business, segments, risk factors and financial statements.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the nature of new term loans, secured notes, amendments, results of operations and other reported events. Users can also monitor current reports that reference press releases on topics such as investor day presentations, refinancing transactions and quarterly earnings, using this page as a central source for BLCO’s regulatory history and ongoing disclosure record.
Bausch & Lomb Corp director Steven H. Collis filed an initial insider ownership report indicating that he does not beneficially own any company securities. The Form 3 confirms his role as a director of Bausch & Lomb while stating in the remarks that no securities are beneficially owned. A power of attorney is on file, authorizing an attorney-in-fact to sign on his behalf.
Bausch & Lomb Corp director reports no share ownership
Bausch & Lomb Corp (BLCO) director Alfonso Eduardo filed an initial ownership report stating that no securities of the company are beneficially owned. This Form 3 confirms that, as of the reported date, he does not hold Bausch & Lomb common stock or derivative securities in either a direct or indirect capacity.
Bausch + Lomb Corporation amended its existing credit agreement by arranging a new
The Replacement Term Loans amortize at
Bausch + Lomb Corporation announced that it has appointed Eduardo C. Alfonso, MD, and Steven H. Collis to its board of directors, effective January 1, 2026. They are filling vacancies created by the departures of Brett Icahn and Gary Hu from the board in August 2025.
The board determined that both new directors are independent under New York Stock Exchange and Toronto Stock Exchange rules and the company’s corporate governance guidelines. They have not yet been appointed to any board committees, will receive compensation under the standard Non-Employee Directors Compensation Policy, and have entered into the company’s standard director indemnification agreements. The company states there are no special arrangements or related-party transactions involving either new director that require disclosure.
Bausch + Lomb Corporation is refinancing part of its debt by allocating a new $2,802,125,000 tranche of term B loans, called the Replacement Term Loans. The company plans to use the proceeds to refinance its existing term B loans due 2031 and its term B loans due 2028.
The Replacement Term Loans are expected to carry a margin of 3.75% per year for loans tied to term SOFR and 2.75% per year for loans tied to the alternate base rate, reducing the margin by 0.50% on the 2031 loans and 0.25% on the 2028 loans. The new loans will mature on January 15, 2031, matching the current 2031 maturity and extending the 2028 loans’ maturity to that date. The company expects the refinancing to close in the first quarter of 2026 but notes there is no assurance it will be completed on these terms or at all.
Bausch & Lomb Corp (BLCO) reported that one of its directors acquired additional equity in the company. On 11/14/2025, the director acquired 1,642 common shares at a price of $15.60 per share. Following this transaction, the director beneficially owns 66,556 common shares in total, held directly. An accompanying note explains that the reported amount reflects restricted share units, each representing a contingent right to receive one common share of Bausch + Lomb Corporation.
Bausch & Lomb Corp. director reports equity award under Form 4. A company director acquired 1,402 common shares of Bausch & Lomb Corp. on 11/14/2025, coded as an acquisition and priced at $15.60 per share. After this transaction, the director beneficially owned a total of 71,367 common shares held directly. The new shares are in the form of restricted share units, each representing a contingent right to receive one common share of Bausch & Lomb Corporation.
Bausch + Lomb furnished an update tied to its Investor Day on November 13, 2025. The company announced that the event will cover three-year financial targets, details on pipeline products, and a re-affirmation of previously announced guidance for the fiscal year ending December 31, 2025.
A press release and a slide presentation were posted to the company’s website and furnished as Exhibits 99.1 and 99.2. A webcast and replay are available on the Investor Relations section of the site. The materials are being furnished under Regulation FD and are not deemed filed or incorporated by reference.
Bausch + Lomb reported Q3 2025 results with revenue of $1,281 million, up from $1,196 million a year ago, and operating income of $95 million versus $43 million. The quarter showed a net loss attributable to the company of $28 million (–$0.08 per share) compared to net income of $4 million ($0.01) last year, reflecting higher interest expense and other below‑the‑line items despite stronger operations.
For the first nine months, revenue reached $3,696 million (from $3,511 million) and the company recorded a net loss of $302 million (from $314 million). Cash from operations was $147 million, while investing cash outflows of $267 million included higher capex. Long‑term debt stood at $4,922 million and cash and equivalents at $310 million as of September 30, 2025. Bausch Health owned about 88% of BLCO as of October 22, 2025, and the planned separation remains subject to conditions. Shares outstanding were 354,189,784 as of October 22, 2025.
FAQ
What is the current stock price of Bausch + Lomb Corporation (BLCO)?
What is the market cap of Bausch + Lomb Corporation (BLCO)?
